Since most CM has activating mutations in the proto-oncogene BRAF, which is part of the Ras-Raf-MeCMk-Erk signaling pathway, this provides an essential direction for targeted therapy in melanoma targeting the MAPK pathway (BRAF and MEK inhibitors) [99]. The gene discussed is BRAF; the disease is melanoma.